Losartan Potassium Tablet, Film Coated
Product Images NDC 68382-136

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68382-136). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C516a5a7 Cfc8 4b3b A8bc 7644c3313673 01

Chemical structure of Losartan Potassium, showing the molecular arrangement of atoms including chlorine, potassium ion, and aromatic rings.*

FDA Label Image

C516a5a7 Cfc8 4b3b A8bc 7644c3313673 02

A line graph comparing the percentage of patients with a primary endpoint over study months for Atenolol and Losartan Potassium. The x-axis represents study months up to 66, while the y-axis shows the percentage of patients up to 16%. Atenolol is shown with a dashed line and Losartan Potassium with a solid line, indicating a trend in risk reduction.*

FDA Label Image

C516a5a7 Cfc8 4b3b A8bc 7644c3313673 03

A line chart comparing the percentage of patients with fatal or non-fatal stroke over 66 months of study for Atenolol and Losartan Potassium. The y-axis shows the percentage of patients, and the x-axis shows the study months. The graph indicates adjusted risk reduction with Losartan Potassium compared to Atenolol, with a p-value of 0.001.*

FDA Label Image

C516a5a7 Cfc8 4b3b A8bc 7644c3313673 04

A forest plot comparing hazard ratios with 95% confidence intervals for Losartan Potassium versus Atenolol in primary composite and stroke (fatal/non-fatal) outcomes. The plot includes subgroup analyses by age, gender, race, ischemic heart disease (ISH), diabetes, and history of cardiovascular disease (CVD), displaying event rates and hazard ratios favoring either Losartan Potassium or Atenolol.*

FDA Label Image

C516a5a7 Cfc8 4b3b A8bc 7644c3313673 05

A line graph showing the percentage of patients with events over 48 months for Losartan Potassium tablets compared to placebo. The solid line represents Losartan Potassium, and the dotted line represents placebo, indicating a 16.1% risk reduction with statistical significance (p=0.022).*

FDA Label Image

C516a5a7 Cfc8 4b3b A8bc 7644c3313673 06

Losartan Potassium 25 mg film-coated tablets label showing the drug name, strength, and form. The packaging indicates 30 tablets per bottle, Rx only. It includes manufacturer information from Zydus Pharmaceuticals USA Inc. The label displays dosage storage instructions and cautionary statements for patient and pharmacist use.*

FDA Label Image

C516a5a7 Cfc8 4b3b A8bc 7644c3313673 07

Losartan Potassium Tablets USP 50 mg film-coated tablets packaging label. The label includes an image of two white oval tablets, one with the imprint '216'. The package contains 30 tablets, labeled for prescription use only (Rx only). The labeler is Zydus Pharmaceuticals USA Inc., with manufacturing by Cadila Healthcare Ltd., India. Storage and dosing instructions are partially visible on the label.*

FDA Label Image

C516a5a7 Cfc8 4b3b A8bc 7644c3313673 08

Losartan Potassium Tablets USP 100 mg film-coated tablets label from Zydus Pharmaceuticals USA Inc. The label includes the NDC 68382-137-06 and shows a single tablet imprinted with 'Z18'. It states a quantity of 30 tablets, prescription use only. Storage instructions and manufacturer/distributor information are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.